Dr. Rossi is an experienced drug development executive with a track record of product development and approval in large and small pharmaceutical companies. He has raised significant capital and has brought multiple products through all stages of development and regulatory approval. He is a co-founder and the Chairman of Arkayli Biopharma, Inc, whose lead product is a preclinical topical formulation for the treatment of infantile hemangiomas. Recently, he served as the Chief Executive Officer of Venthera, Inc., a company developing a topical formulation of a novel PI3Ka inhibitor as a potential treatment of venous and lymphatic malformations. In his past CEO roles at Agile Therapeutics and SansRosa he raised over $60 million dollars of capital and created two commercial products: Twirla® a 7-day contraceptive patch and Mirvaso® a first-in-class treatment for the erythema of rosacea. He held various roles in drug development organizations of two major pharmaceutical companies: Johnson & Johnson and SmithKline Beecham. At Johnson & Johnson, he served as the Vice President of Global Pharmaceutical and served on the board of The R.W. Johnson Pharmaceutical Research Institute. He earned his Ph.D. in Chemistry from Texas A&M in 1985, and his B.A. in Chemistry from Western Connecticut State University in 1980. He is the author of numerous scientific publications, inventor of numerous patents, a frequent speaker at national and international scientific meetings, and a member of the American Chemical Society, The International Society for the Study of Vascular Anomalies, and the Pediatric Dermatological Research Association.

Dr MacFarlane has more than 35 years of experience in drug development and commercialization of pharmaceutical products. She currently serves as the CEO of Arkayli Biopharma. Prior to Arkayli, Katie was Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to biopharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President of Marketing, Sales and New Product Planning at Warner Chilcott, and Senior Director of Marketing at Parke-Davis (now Pfizer). Dr MacFarlane is a Director of Neurizon Therapeutics (ASX:NUZ) and a former Director of Mayne Pharmaceuticals (ASX:MYX), RespireRx Pharmaceuticals, Inc., and INMED Partnerships for Children, an NGO. Katie is an affiliate faculty member of the Purdue University School of Pharmacy, and a Founding Member and Advisor to IPhO. She has a Bachelor of Science and Doctor of Pharmacy from Purdue University and completed a Postdoctoral Fellowship in Clinical Research with Rutgers University and Hoffmann-LaRoche.

Dr. Drolet has over 30 years of experience in leadership in academic medicine. She has served in successive leadership roles, including the Chief of the Division of Pediatric Dermatology, the Medical Director of the Vascular Anomalies Center, Clinical Vice President of Ambulatory Services, and Chief Experience Officer at the Children’s Hospital of Wisconsin. In March of 2019, Dr. Drolet was named Geneva F. and Sture Johnson Distinguished Chair of the Department of Dermatology at the University of Wisconsin-Madison. Her research has focused on discoveries related to birthmarks, vascular anomalies, and infantile hemangiomas. She has created and led several multi-site research networks focusing on infantile hemangiomas and vascular anomalies. She is past-President of the Society for Pediatric Dermatology and past-President of Hemangioma of Infancy Group (HIG). Dr. Drolet has published over 175 peer-reviewed manuscripts. By leveraging next-generation sequencing technology, her team has helped to identify genetic causes of vascular anomalies and set the stage for the development of novel targeted therapies. Her varied experiences in healthcare administration and research, along with her broad exposure to patient and family perspectives, have resulted in the development of innovative approaches to patient-centered care delivery. Her research efforts have been supported by the National Institute of Health, Greater Milwaukee Foundation, Dermatology Foundation, and Pediatric Dermatology Research Alliance.

Dr. Price is the CEO of NeuroBo Pharmaceuticals NRBO (NASDAQ). He has decades of experience as the head of Safety Management Teams, multiple Data Safety Monitoring Boards, as well as protocol development and safety support from FIH to Phase IV clinical trials. Dr. Price was Chief Medical Officer of the pharmacovigilance team of ProPharma Group, a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. Previous to that, he served as Chief Executive Officer and Chief Medical Officer of Drug Safety Solutions, Inc. until its acquisition by ProPharma Group in 2017. From 1997 to 2002, Dr. Price was the Director of Clinical Development for Oncology at MedImmune, Inc., which is now the biologics subsidiary of AstraZeneca plc. Dr. Price has served on multiple corporate boards, including TSX (NYSE) and RNN (NYSE). In his previous role with Sarepta Therapeutics SRPT (NASDAQ), he helped to guide the company's transition from $80 million market cap (2008) to its 2019 market cap of $8.4 billion. Dr. Price is a clinical physician trained in internal medicine and is a former member of the American Medical Association, the Academy of Pharmaceutical Physicians, and the American Society for Microbiology. Dr. Price received a B.A. from the University of Rio Grande and an M.D. from the University of Santiago.

Elizabeth M. Hagerman, Ph.D., currently serves as Chief Innovation Officer for UW Health and Executive Director of UW Health’s Isthmus Project, an innovation initiative in partnership with the UW School of Medicine. Elizabeth is responsible for operations of the Isthmus Project, which provides a place for healthcare innovators to seek support for their ideas that aim to achieve better health outcomes or to solve problems facing UW Health patients, providers and the health system.

Elizabeth’s experience includes a series of industry and academic roles focused on biotechnology, product development and commercialization as well as collaborations between industry and academia. She was most recently the Chief Innovation and Strategy officer at Conexus Indiana, whose mission is to lead innovative collaborations among industry, academic and public partners. Prior to that, Elizabeth served as Vice President of Rose-Hulman Ventures, a leading university model for offering prototyping and product development services to companies while providing engineering internships to undergraduate students. Elizabeth began her career at Baxter Healthcare in the regenerative medicine business with roles in R&D, business development and medical affairs.

Hagerman earned her bachelor’s degree in chemical engineering from the Rose-Hulman Institute of Technology, and both master’s and Ph.D. degrees in biomedical engineering from the University of California-Los Angeles.

Mr. Hall brings over 33 years of experience in the Bio-Pharmaceutical industry. His extensive experience spans Sales, Marketing, Medical Affairs, Managed Care and Strategy. He is a proven builder of teams who is best known for his cross-functional mindset that bridges Commercial Operations and Medical Affairs. He brings launch experience from multiple therapeutic areas and offers a unique perspective on platform design and business development. Mr. Hall served as Vice President of Medical Affairs at MedImmune, where he led Medical Operations, Field Operations and Medical Strategy. Following the acquisition of MedImmune by Astra Zeneca, he led the design team that integrated MedImmune’s Medical Affairs function into the North American Business Unit of Astra Zeneca. Prior to his leadership roles in Medical Affairs, he held various positions at MedImmune in Marketing and Sales Leadership. Mr. Hall spent the first 11 years of his career with Hoffmann-La Roche in sales and management roles where he successfully built and led several teams. Over the past nine years, Mr. Hall has been a public and private side investor in the life-science space through his private office at wisdomGame, LLC. He holds a B.A. in Economics and Political Science from Wofford College in Spartanburg, SC.

Al Altomari brings extensive experience in pharmaceutical development, commercialization, and dealmaking to his advisory role at Arkayli. Mr. Altomari guided the merger of Agile Therapeutics into InSud Pharma, in which Agile’s Common Shareholders received a significant premium of approximately 350%. Mr. Altomari began serving as Chairman and CEO of Agile Therapeutics in 2010. Before joining Agile Therapeutics, Mr. Altomari served as CEO of Barrier Therapeutics. In 2008, he completed the successful sale of the company to GSK/Stiefel Laboratories. His initial role with Barrier had been as Chief Commercial Officer, beginning in August 2003; he was promoted to COO in February 2006, and he was named CEO in 2008. Prior to joining Barrier, Mr. Altomari worked in numerous executive roles in general management, commercial operations, business development, product launch preparation and finance within Johnson & Johnson from 1982 to 2003. He concluded his tenure with Johnson & Johnson as the first General Manager of Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. He also served as Vice President/Franchise Head of Ortho-McNeil Pharmaceutical’s Women’s Health Care Franchise. Mr. Altomari began his career in Finance at Johnson & Johnson.

Mr. Altomari has served on the Board of Insmed Inc. and multiple public biotech Boards, including Baudax Bio, Recro Pharma, Auxilium Pharmaceuticals (acquired by Endo Therapeutics) and Dusa Pharmaceuticals (acquired by Sun Pharma). He also previously served on the Board of BioNJ. In 2017 and 2020, he was listed in the “100 Most Inspiring People” in PharmaVoice Magazine. He was named CEO of the Year by the New Jersey Technology Council in 2014 and was a finalist for the New Jersey Entrepreneur of the Year by Ernst & Young (2012).

Mr. Altomari was elected as a Drexel University Trustee in 2020 and serves on the Academic and Finance & Human Resource Committees. At Drexel, he is also a member of the Advisory Board of the Close School (School of Entrepreneurship), the Applied Innovation External Advisory Board, and the Dean's Advisory Board at LeBow (School of Business), having previously served as the Chair. He currently is a Trustee on the St. Christopher’s Hospital for Children Partners Board and is on the Board of Medina Health Center. He also previously served on the board of TASK (Trenton Area Soup Kitchen). In 2017, he was named to the Drexel 100 ranks. Also in 2017, he was named to the Hall of Fame at Father Judge High School.